Macular Edema - Pipeline Review, H1 2012

Global Markets Direct, March 2012, Pages: 65

Macular Edema – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Macular Edema - Pipeline Review, H1 2012', provides an overview of the Macular Edema therapeutic pipeline. This report provides information on the therapeutic development for Macular Edema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Edema. 'Macular Edema - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Macular Edema.
- A review of the Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Macular Edema pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Macular Edema.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Macular Edema pipeline depth and focus of Macular Edema therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Macular Edema Therapeutic Products under Development, Key Players in Macular Edema Therapeutics, Macular Edema Pipeline Overview, Macular Edema Pipeline, Macular Edema Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Macular Edema Overview
Therapeutics Development
An Overview of Pipeline Products for Macular Edema
Macular Edema Therapeutics under Development by Companies
Macular Edema Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Macular Edema Therapeutics – Products under Development by Companies
Macular Edema Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Macular Edema Therapeutics Development
Allergan, Inc.
Dyax Corp.
SANWA KAGAKU KENKYUSHO CO.,LTD.
Icon Bioscience, Inc.
Macular Edema – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
DX-88 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IBI-20089 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SK-0503 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Raptiva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon alpha 2a + prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xibrom - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Actimmune - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Triamcinolone Acetonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Infliximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lucentis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Microplasmin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Triamcinolone + Vitrectomy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lucentis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AGN208397 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Visudyne Photodynamic Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Trientine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ranibizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Macular Edema Therapeutics – Drug Profile Updates
Macular Edema Therapeutics – Discontinued Products
Macular Edema Therapeutics - Dormant Products
Macular Edema – Product Development Milestones
Featured News & Press Releases
Jan 13, 2012: Genentech Announces First Milestone Payment To ForSight VISION4 For Development Of Sustained Delivery Of Lucentis
Nov 24, 2011: NICE Rejects Lucentis For Treatment Of Visual Impairment Caused By Macular Oedema
Aug 03, 2011: NICE Gives Positive Recommendation To Dexamethasone For Treatment Of Common Eye Condition In Final Guidance
Jun 06, 2011: Novartis Gains European Commission Approval For Lucentis To Treat Vision Loss Due To Macular Edema Secondary To RVO
Jun 06, 2011: NICE Recommends Allergan's OZURDEX For Treatment Of Retinal Vein Occulsion
May 04, 2011: Promedior Presents Preclinical Data At ARVO Demonstrating PRM-151 Reduces Neovascularization In Retinal Diseases
Feb 11, 2011: Genentech's Lucentis Phase III Study Meets Primary Endpoint For Improving Vision In Patients With Diabetic Macular Edema
Dec 20, 2010: Bayer And Regeneron Report Positive Results For VEGF Trap-Eye In Central Retinal Vein Occlusion And Diabetic Macular Edema
Jun 23, 2010: Genentech says Lucentis gets added FDA approval
Jun 22, 2010: Genentech Receives FDA Approval For Lucentis For Treatment Of Macular Edema Following Retinal Vein Occlusion
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Macular Edema, H1 2012
Products under Development for Macular Edema – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Allergan, Inc., H1 2012
Dyax Corp., H1 2012
SANWA KAGAKU KENKYUSHO CO.,LTD., H1 2012
Icon Bioscience, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Macular Edema Therapeutics – Drug Profile Updates
Macular Edema Therapeutics – Discontinued Products
Macular Edema Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Macular Edema, H1 2012
Products under Development for Macular Edema – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Global Age-Related Macular Degeneration Drug Pipeline Capsule - 2012
• Nausea – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013